Search

Your search keyword '"Paolo Pella"' showing total 5 results
Start Over Author "Paolo Pella"
5 results on '"Paolo Pella"'

1. Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)

Author

Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, and the BRIGHT Study Group

Subjects
brodalumab, effectiveness, observational, psoriasis, real‐world, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for systemic treatment. Objectives This study evaluated the achievement and maintenance of therapeutic response for 1 year in psoriasis patients treated with brodalumab in the Italian clinical practice. Methods Real‐world, multicenter, observational, retrospective and prospective study. The retrospective phase ranged from enrolment visit to initiation of brodalumab (12 ± 4 weeks before). The prospective phase ranged from enrolment to a routine follow‐up visit set after 52 ± 4 weeks. Results One hundred eighty‐four patients were eligible and 164 completed the observation period (median 11.9 months; Q1–Q3: 11.4–12.3). At enrolment, the mean duration of disease was 13.9 years (standard deviation; 13.3), 94% of patients (N = 172) had ≥1 clinical manifestation of psoriasis, mainly erythema and itching, and 95.6% had received ≥1 antipsoriatic treatment before brodalumab. Patients who reached an absolute Psoriasis Area and Severity Index (PASI) score ≤3 at week 12 and maintained it ≤3 through week 52 were 97 (64.7%). At week 12, 72.7% of patients achieved PASI 75, 54.5% PASI 90 and 42.0% PASI 100. At Week 52, 92.9% of patients achieved PASI 75, 84.4% PASI 90 and 61.7% PASI 100. A static Physician's Global Assessment (sPGA) score = 0 was obtained by 55.0% of patients after 12 weeks of brodalumab and by 77.0% after 52 weeks. A Dermatology Life Quality Index ≤1 was reported by 71.9% of patients after 12 weeks and by 89.9% after 52 weeks of treatment. No significant outcome differences were shown among patient subgroups defined by previous antipsoriatic treatments (none, systemic other than biologics or biologic) at either brodalumab initiation or any of the subsequent study visits. Conclusions In this real‐world setting, brodalumab was rapidly effective on skin lesions and quality of life both in biologic‐naïve and biologic‐experienced moderate‐to‐severe psoriasis patients, with a favourable safety profile.

Published
2023
Full Text
View/download PDF

3. Sharing Patient and Clinician Experiences ofModerate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon PatientWellbeing

Author

Francesca, Prignano, Brunasso, Alexandra M. G., Gabriella, Fabbrocini, Giuseppe, Argenziano, Federico, Bardazzi, Borroni, Riccardo G., Martina, Burlando, Anna Elisabetta Cagni, Elena, Campione, Elisa Cinotti, Aldo Cuccia, Stefano Dastoli, Rocco De Pasquale, Clara De Simone, Vito Di Lernia, Valentina Dini, Maria Concetta Fargnoli, Elisa Faure, Alfredo Giacchetti, Claudia Giofrè, Girolomoni, Giampiero, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Maria AntoniaMontesu, Paolo Pella, Paolo Pigatto, Antonio Giovanni Richetta, Elena Stroppiana, Marina Venturini, Leonardo Zichichi, and Stefano, Piaserico

Subjects
health-related quality of life, wellbeing, physicians, surveys and questionnaires, perspective, psoriasis, patients
Published
2022

4. Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing

Author

Francesca Prignano, Alexandra M. G. Brunasso, Gabriella Fabbrocini, Giuseppe Argenziano, Federico Bardazzi, Riccardo G. Borroni, Martina Burlando, Anna Elisabetta Cagni, Elena Campione, Elisa Cinotti, Aldo Cuccia, Stefano Dastoli, Rocco De Pasquale, Clara De Simone, Vito Di Lernia, Valentina Dini, Maria Concetta Fargnoli, Elisa Faure, Alfredo Giacchetti, Claudia Giofrè, Giampiero Girolomoni, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Maria Antonia Montesu, Paolo Pella, Paolo Pigatto, Antonio Giovanni Richetta, Elena Stroppiana, Marina Venturini, Leonardo Zichichi, Stefano Piaserico, Prignano, F., Brunasso, A. M. G., Fabbrocini, G., Argenziano, G., Bardazzi, F., Borroni, R. G., Burlando, M., Cagni, A. E., Campione, E., Cinotti, E., Cuccia, A., Dastoli, S., De Pasquale, R., De Simone, C., Di Lernia, V., Dini, V., Fargnoli, M. C., Faure, E., Giacchetti, A., Giofre, C., Girolomoni, G., Lasagni, C., Lembo, S., Loconsole, F., Montesu, M. A., Pella, P., Pigatto, P., Richetta, A. G., Stroppiana, E., Venturini, M., Zichichi, L., and Piaserico, S.

Subjects
physician, physicians, perspective, psoriasis, General Medicine, patients, health-related quality of life, wellbeing, surveys and questionnaires, surveys and questionnaire, patient, psoriasi
Abstract

A nationwide survey was conducted in adult patients with psoriasis (PsO) across Italy to obtain their real-world perspective of the impact of PsO on their wellbeing. Patients completed a 26-question survey (based on the patient benefit index; PBI, The Dermatology Life Quality Index; DLQI and the World Health Organization-five; WHO-5 wellbeing index) and workshop discussion sessions were undertaken by dermatologists to interpret results from the survey. 392 patients with PsO completed the survey. Analysis of results was restricted to patients who had moderate-to-severe plaque psoriasis (assessed by patients; n = 252; 64.3%). Dermatologists (n = 32) completed one question from the survey related to wellbeing and rated social, physical and mental domains as contributing to a similar extent, with comparable scores also observed by patients. For treatment, biologics yielded higher scores on average, whereas little difference was observed between topical and conventional systemic treatments. Only 23.8% of patients felt that their dermatologist was taking into consideration their wellbeing and 32.6% of the patients considered their therapy as inadequate in improving signs and symptoms of the disease. This survey identified key factors contributing to barriers impacting on patient wellbeing. Simple, but comprehensive questionnaires can provide important insight to patients’ needs that may significantly increase clinician awareness during visits leading to tailored treatment.

Published
2022

5. Reconstruction of the Tarsus-Conjunctival Layer Using a Venous Wall Graft

Author

Cesare Barbera, Monica Ferraro, Paolo Pella, Roberto Manzoni, and Lucio Dodaro

Subjects
Blepharoplasty, Male, medicine.medical_specialty, Tarsus (eyelids), Conjunctival Neoplasms, Adenocarcinoma, Eyelid Neoplasms, Transplantation, Autologous, Surgical Flaps, Veins, medicine, Humans, Aged, Aged, 80 and over, Invasive carcinoma, business.industry, Eyelids, General Medicine, Middle Aged, Venous wall, Surgery, Ophthalmology, medicine.anatomical_structure, Carcinoma, Basal Cell, Female, Eyelid, business, Conjunctiva
Abstract

PURPOSE The repair of full-thickness defects of the eyelids poses a challenge, because the reconstruction of the tarsus-conjunctival layer often results in aesthetically and functionally unsatisfactory outcomes. The authors' aim was to create a new method to repair large tarsus-conjunctival losses and to examine the outcomes of its use. METHODS Seven patients with invasive carcinoma of the eyelids underwent a venous wall graft. RESULTS All patients had good to outstanding results and no complications. CONCLUSION This new reconstruction of the deeper layer of the eyelid provides a useful alternative to traditional methods (composite grafts and full-thickness flaps). Our new surgical technique is easy to execute and has good functional and aesthetic results.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results